Hope Medicine Reports the Data from P-II Trial of HMI-115 for Treating Endometriosis
Shots:
- HopeMed reported interim data from a global P-II trial assessing the safety & efficacy of HMI-115 (240mg, Q2W) vs PBO to treat women (n=142) with moderate to severe endometriosis-related pain for over 12wks. in the US, Poland & China
- In the first 102 patients analyzed, HMI-115 showed a 42% reduction in dysmenorrhea pain and a 50% mean reduction in non-menstrual pelvic pain; most of them had normal menstrual cycles without peri-menopausal symptoms or significant changes in bone density or hormone levels. It was well-tolerated without any serious TRAEs
- HMI-115 is a monoclonal antibody that works by blocking prolactin receptor for treating endometriosis. It has been designated as a breakthrough therapy by the China’s NMPA
Ref: Hope Medicine | Image: Hope Medicine
Related News:- Alto Neuroscience’s P-IIb Trial of ALTO-100 for Major Depressive Disorder Couldn’t Achieve its Primary Endpoint
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
